Good morning, everyone, and how are you today? A gorgeous sunrise can be seen from the Pharmalot corporate campus this morning, where we are, as usual, hustling about to get those short people to the schoolhouses and trying to keep the official mascots from waking the neighbors. Of course, things will get still busier from here. And we know you can relate. So grab a cup of stimulation, or a bottle of water, if you prefer, and join us as we dive into another round of meetings and deadlines. Hope all goes well and stay in touch...
Roche Sweetens Illumina Bid To $6.7 Billion (Bloomberg News)
Boehringer Cuts Pradaxa Price By 13 Percent In The UK (Pharma Times)
Health Canada: 8 Percent Of Inspected Trials Are Noncompliant (Regulatory Focus)
FDA Rejects Chelsea Drug For Rare Disease (MedCity News)
FDA Extends Review For Forest Lung Drug (Reuters)
Novartis Patent Case In India Postponed To July (Pharma Times)
HPV Vaccine Rate Down After Vaccine Approval (MedPage Today)
FTC May Rule On Express Scripts Deal For Medco This Week (Bloomberg News)
Oncology Trials Take Longer Than Other Therapeutic Areas (Outsourcing Pharma)
India Defends Compulsory License For Bayer Drug (LiveMint)
UK Probes Pandremix Vaccine Link To Narcolepsy (The Guardian)
Teva Sells Quebec Plant And Transfers Staff To CMO (InPharma Technologist)
Allergan Seeks Approval To Sell Botox For Overactive Bladder (Dow Jones)
Sermo Taps Revolution Health Veteran As CEO (Xconomy)
EDITOR'S NOTE: Please check this post for updates throughout the morning
sunrise pic thx to benimoto on flickr
2 Comments
May I observe that we have a LOT of Little today. I can't wait to see what the Pharmalot "A team" will be - based on the size and scope of the second string.
Less is more.